Share

FDA Grants Clearance for Digital Application for T2D Patients

The U.S. Food and Drug Administration (FDA) today granted 510(k) clearance for a global digital solution that supports the effective management of type 2 adult diabetes patients treated with basal insulin. The application will be marketed as Insulia® by the company Voluntis, which specializes in therapeutic companion software to help patients self-manage chronic diseases. Insulia® Diabetes Management Companion...
Share

Case of the Month ESAP Special Edition: Diabetes and Aging

esap cover This issue highlights a special edition of ESAP, available for a limited time. Test your clinical knowledge with this free case to discover the rich intellectual legacy of endocrinology. Available on the online store. Clinical Vignette A 63-year-old man is referred for management of diabetes mellitus. His history is remarkable for adrenal insufficiency that occurred...
Share

I’m Still Here: Diabetes & The Aging Patient

elderly-patient-closeup As diabetes patients are living longer, endocrinologists are finding themselves faced with a unique set of treatment challenges not often found in younger patients. From cognitive function to cultural norms, treating older diabetes patients is much more complicated than ever before. During the Endocrine Society’s 97th annual meeting in San Diego, Pendar Farahani, MD, MSc,...
Share

The American Diabetes Association Releases Psychosocial Recommendations for Medical Providers

Guidelines encourage comprehensive, personalized mental health assessment and treatment as part of routine diabetes care Living with diabetes can be challenging on many levels, and complex environmental, social, behavioral and emotional issues—known as psychosocial factors—influence the health of people living with the disease, as well as their ability to manage their diabetes. The American Diabetes...
Share

Positive Results in Phase 2b Study of Metformin Delayed Release in Type 2 Diabetes

Positive results were reported last week in a Phase 2b dose-ranging study, which met the primary endpoint of showing a statistically significant reduction in HbA1c at 16 weeks with delayed-release metformin compared with placebo in subjects with type 2 diabetes. Elcelyx Therapeutics is marketing this drug as Metformin DR, an investigational product designed to target metformin delivery to...

Diabetes Research Articles

Get the most up to date news on diabetes research and treatment. For more information read the latest issue of Endocrine News.